AbbVie/Roche’s venetoclax hits goals in CLL trial

19th September 2017 Uncategorised 0

A combination of AbbVie and Roche’s venetoclax and rituximab has shown a progression-free survival benefit in patients with chronic lymphocytic leukaemia (CLL).

More: AbbVie/Roche’s venetoclax hits goals in CLL trial
Source: News